KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Debt to Equity (2017 - 2020)

Xenon Pharmaceuticals (XENE) has disclosed Debt to Equity for 4 consecutive years, with $0.08 as the latest value for Q1 2020.

  • On a quarterly basis, Debt to Equity fell 49.15% to $0.08 in Q1 2020 year-over-year; TTM through Mar 2020 was $0.08, a 49.15% decrease, with the full-year FY2019 number at $0.17, changed N/A from a year prior.
  • Debt to Equity was $0.08 for Q1 2020 at Xenon Pharmaceuticals, down from $0.17 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.24 in Q1 2018 to a low of $0.08 in Q1 2020.
  • A 4-year average of $0.18 and a median of $0.18 in 2019 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: surged 54.24% in 2019, then tumbled 49.15% in 2020.
  • Xenon Pharmaceuticals' Debt to Equity stood at $0.19 in 2017, then decreased by 29.27% to $0.13 in 2018, then rose by 26.15% to $0.17 in 2019, then crashed by 50.64% to $0.08 in 2020.
  • Per Business Quant, the three most recent readings for XENE's Debt to Equity are $0.08 (Q1 2020), $0.17 (Q4 2019), and $0.21 (Q3 2019).